Sancuso (SP-01) is a long-acting transdermal system, delivering the anti-emetic, granisetron, steadily into the patient’s bloodstream over seven days without the need for injections or swallowing pills.
Sancuso is the first and only commercialized long-acting granisetron transdermal product, said Solasia.
Solasia also indicated that it has started regulatory and clinical development work of SP-01 in China. Solasia has engaged Excel PharmaStudies, a Chinese contract research organization, to assist an in-house team in preparing and carrying out clinical trials of SP-01 in China.
To support the development of Sancuso and future pipeline products, the company said that it has also expanded its clinical development and regulatory staff.
Yoshihiro Arai, executive vice president of development at Solasia, said: “The Solasia team is excited to initiate clinical development of Sancuso, a product that will provide comfort and relief to many Japanese and Chinese cancer patients suffering from nausea and vomiting associated with chemotherapy.”